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ABSTRACT 
Objective: The present study aimed to develop a stability indicating ultra-performance liquid chromatography (UPLC) method for the estimation of 
panobinostat lactate in pharmaceutical dosage form and validate the method in accordance with ICH guidelines.  
Methods: The optimized conditions for the developed UPLC method are acquity UPLC hibar C18 (100 mm × 2.1 mm, 1.8µ) column maintained at 
30°C with mobile phase consisting of 0.1% ortho phosphoric acid and acetonitrile in the ratio 50:50%v/v on isocratic mode at flow rate 0.3 ml/min. 
The sample was detected at 266 nm.  
Results: The retention time for panobinostat was found to be 1.6 min. The developed method was validated for accuracy, precision, specificity, ruggedness, 
robustness and solution stability. The method obeyed Beer’s law in the concentration range of 50µg/ml and 300µg/ml with correlation coefficient of 0.9998. 
Forced degradation studies were conducted by exposing the drug solution to various stress conditions such as acidic, basic, peroxide, neutral, photolytic and 
thermal conditions. The net degradation was found to be within the limits, indicating that drug is stable in stressed conditions. 
Conclusion: The developed method for the estimation ofpanobinostat can be utilized for the routine analysis of pharmaceutical dosage form.  
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Panobinostat [1–5] (fig. 1), chemically defined as 2-Hydroxypropanoic 
acid, compd. with 2-(E)-N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-
yl)ethyl]amino]methyl]phenyl]-2-propenamide (1:1). It is white to 
slightly yellowish or brownish powder, slightly soluble in water. It has 
pKa values of 5.45 and 10.01. It belongs to anticancer category which 
acts by inhibiting multiple histone deacetylase enzymes, a mechanism 
leading to apoptosis of malignant cells via multiple pathways. It is used 
for the treatment of multiple myeloma [6, 7].  
The literature survey reveals that there was only one method 
developed and validated for the estimation of Panobinostat using 
ultra-high performance liquid chromatography–mass spectrometry 
[8]. As there is no method reported using UPLC, the present study 
aimed to develop and validate an UPLC stability indicating method 
for the estimation of panobinostat in pharmaceutical dosage form. 
 
 
Fig. 1: Chemical structure of panobinostat 
 
MATERIALS AND METHODS  
Reagents and chemicals 
Panobinostat working standard was procured from spectrum labs, 
Hyderabad as gift sample. The farydak tablets were purchased from 
local pharmacy. All the chemicals used were of AR grade purchased 
from Merck, Mumbai. All the solvents used were of HPLC grade 
purchased from Sigma-Aldrich, Mumbai.  
Chromatographic conditions and instruments 
The ACQUITY UPLC [9, 10] system equipped with binary solvent 
manager, sample manager, ultra violet (UV) detector and Hibar 
C18 (100 mm × 2.1 mm, 1.8µ) column was used for the 
determination of panobinostat. The optimized conditions 
included 0.1% ortho phosphoric acid (OPA) and acetonitrile 
(50:50%v/v) as mobile phase run on an isocratic mode at flow 
rate 0.3 ml/min. The column was maintained at 30°C and 
detection was done at 266 nm. Other equipment used in the 
method was pH meter, ultrasonic bath sonicator and weighing 
balance.  
Preparation of diluent 
Mixture of water and acetonitrile in the ratio 50:50%v/v was used 
as diluent. 
Preparation of mobile phase 
Mixture of 0.1% ortho phosphoric acid and acetonitrile in the ratio 
50:50%v/v was used as mobile phase. 
Preparation of Standard and Sample solutions 
200 mg of panobinostat working standard was dissolved in 100 ml 
of diluent. 1 ml of the above stock solution was diluted to 10 ml 
using diluent in order to get a concentration of 200µg/ml. 
20 Tablets (Farydak) were weighed accurately and average weight 
was calculated. An amount equivalent to 200 mg of drug was 
dissolved in 100 ml of diluent. Filtered the solution and diluted 1 ml 
of above solution to 10 ml with diluent. 
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The developed method was validated in compliance with International 
Conference on Harmonization (ICH) guidelines [11, 12].  
Specificity 
The specificity of the method was determined by comparing the 
drug solution with the placebo solution and observed for the 
interference of placebo peak with drug peak.  
Accuracy 
Accuracy of the method was determined by % recovery. The drug 
solution along with sample was prepared in three concentration 
levels 50%, 100% and 150%. Then the % recovery was calculated. 
Precision 
Precision of the method was estimated by injecting the six solutions 
of standard into the UPLC system and % relative standard deviation 
(RSD) was calculated.  
Linearity 
Linearity of the method was determined by preparing series of 
dilutions ranging from 50µg/ml–300µg/ml and injecting them into 
UPLC system.  
Ruggedness 
Ruggedness was determined by injecting the six solutions of 
standard into UPLC for different days. The %RSD was calculated. 
Robustness 
Robustness of the method was determined by varying the optimized 
analytical conditions such as mobile phase composition by±5%, flow 
rate by±0.1 ml/min and column oven temperature by±5°C. 
Solution stability 
Solution stability was estimated by analyzing the standard drug 
solution after storage for 24hours under laboratory conditions.  
Forced degradation studies 
Forced degradation studies [13] were carried out for drug by 
exposing the drug solution to the various stress conditions such as 
acidic (2N hydrochloric acid for 30 min at 60 °C), basic (2N sodium 
hydroxide for 30 min at 60 °C), peroxide (20% hydrogen peroxide 
for 30 min at 60 °C), neutral (refluxing the drug in water for 6 
hours at 60°C), photolytic (105 °C for 6h) and thermal (exposing 
the drug solution to UV Light by keeping the beaker in UV 
Chamber for 7days or 200 Watt hours/m2 
  




Fig. 2: UV Spectrum of panobinostat 
 
 
Fig. 3A: Standard chromatogram 
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Fig. 3B: Sample chromatogram 
 
 
Fig. 3C: Blank chromatogram 
 
 
Fig. 4: Linearity plot of panobinostat 
 
 
Fig. 5: Placebo chromatogram 
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Table 1: System suitability and validation parameter results 
Parameter Result(mean±SD) 
Precision (%RSD, n) 0.98(100.13±0.98) 
Accuracy (% Recovery, n mean±SD) 99.46% ±0.29- 99.98% ±0.16 
Specificity Specific, No interference 
Linearity range (µg/ml) 50 – 300 
Correlation coefficient, r 0.9998 
Limit of Detection (µg/ml) 0.19 
Limit of Quantitation (µg/ml) 0.57 
Ruggedness (%RSD, n) Day 1 Day 2 
 1.7 1.7 
Robustness (%RSD, n) Less flow rate 1.4 More flow rate 0.3 
(Organic) Less mobile phase  1.3 More mobile phase (Organic) 1.0 
 Less column temperature 0.8 More column temperature 1.1 
Solution stability  
(%RSD, n) 
(% Assay, n) 
USP Plate count 
USP Tailing factor 
      Day 1 (0 h)                              Day 2 (After 24 h) 
        1.7                                           1.7 
        100.13±0.98                            99.80±1.67 
        3434 
        1.46 
n–number of samples, i.e., six samples for estimation 
 
Table 2: Forced degradation studies result 
Stress condition % Assay % area of degradation peak % Degradation 
2N HCl for 30 min at 60 °C 95.90 3.65 4.10 
2N NaOH for 30 min at 60 °C 94.37 - 5.63 
20% H2O2 97.10  for 30 min at 60 °C - 2.90 
Water for 6h at60 °C 99.32 - 0.68 
UV light 200wts/h or 7 d 98.68 - 1.32 
105 °C for 6h 98.04 - 1.96 
 
 
Fig. 6A: Acid degradation chromatogram 
 
 
Fig. 6B: Base degradation chromatogram 
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Fig. 6C: Peroxide degradation chromatogram 
 
 
Fig. 6D: Water stress study chromatogram 
 
 
Fig. 6E: Photo stability degradation chromatogram 
 
 
Fig. 6F: Dry heat study chromatogram 
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For the development of method for the estimation of 
panobinostat in pharmaceutical dosage form initially many 
mobile phases and many columns were tried to elute the drug 
peak with less tailing factor and more plate count.  
Acquity UPLC Hibar C18 (100 mm × 2.1 mm, 1.8µ) column and 
0.1% OPA: Acetonitrile (50:50%v/v) as mobile phase were 
selected based on peak parameters. The detection wavelength 
was found to be 266 nm as shown in fig. 2 of UV spectrum.  
Prepared standard solution, sample solution and blank solution 
were injected into the UPLC system and system suitability 
parameters were noted as summarized in table 1 along with 
chromatograms as shown in fig. 3A, 3B and 3C respectively.  
The developed method was found to obey Beer’s law in the 
concentration range of 50µg/ml–300µg/ml with correlation 
coefficient of 0.9998. A linearity graph was plotted between 
concentration and peak area as shown in fig. 4 and results are 
summarized in table 1. 
The method was found to be accurate as the % recovery was 
99.46%-99.98% and was within the limits. The % RSD was found to 
be 0.98, indicates that the method was precise. The method was 
found to be specific, as there is no interference of retention time of 
placebo peak with that of drug peak. The placebo chromatogram 
was shown in fig. 5. 
Forced degradation studies results indicate that the drug was found 
to be stable in various stress conditions as net degradation was 
found to be within the limits. The chromatograms were shown in fig. 
6 and results were summarized in table 2.  
CONCLUSION 
A specific, accurate, precise stability indicating method was 
developed for the estimation of panobinostat in pharmaceutical 
dosage form using UPLC. The method was validated by using various 
validation parameters and the method was found to be linear, 
precise, accurate, specific and robust. From the degradation studies 
conducted it is concluded that panobinostat were more stable at 
more concentrations of acid, base, peroxide, thermal, UV and water 
stress study conditions. The run time was 3 min which enables rapid 
quantitation of many samples in routine and quality control analysis 
of tablet formulations. 
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